"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words eight years ago from the mother of a child with Fanconi anemia (FA).

Around 1,200 people with advanced breast cancer could benefit from a decision by NICE to give the go-ahead to a new treatment ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.

Patients with a form of breast cancer in England will be offered a new treatment after it was given the green light for NHS ...

It has been a long, hard first week back in the office, but there is light at the end of the tunnel. Friday has finally ...

Breast Cancer Now said olaparib will be an ‘valuable alternative’ for patients with a certain type of secondary breast cancer.

A groundbreaking study led by the Mayo Clinic Comprehensive Cancer Center has significantly deepened our understanding of ...

A landmark study overturns common beliefs about breast cancer surgery, revealing new insights into treatment choices and ...

Bad memory? Poor sleep habits? These inherited traits may come from your parents. But who's to blame? Here's what the science ...

The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.

Scientists have taken a significant step in understanding mutations in the BRCA2 gene, associated with increased cancer risk, ...

"It's fantastic news that olaparib has been approved for use on the NHS in England, providing a second targeted treatment option for certain people with locally advanced or secondary breast cancer who ...